Avanir Pharmaceuticals (AVNR) Reports In-Line Q4 Loss of 9c/Share

Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q4 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $12.9 million.

For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Aon names interim CFO as Edmund Reese exits the firm
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30